BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28064208)

  • 1. Work disability in non-radiographic axial spondyloarthritis patients before and after start of anti-TNF therapy: a population-based regional cohort study from southern Sweden.
    Wallman JK; Jöud A; Olofsson T; Jacobsson LTH; Bliddal H; Kristensen LE
    Rheumatology (Oxford); 2017 May; 56(5):716-724. PubMed ID: 28064208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
    Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
    Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study.
    Kristensen LE; Petersson IF; Geborek P; Jöud A; Saxne T; Jacobsson LT; Englund M
    Rheumatology (Oxford); 2012 Feb; 51(2):243-9. PubMed ID: 21565900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of work disability after start of anti-TNF therapy in a national cohort of Swedish patients with rheumatoid arthritis: does early anti-TNF therapy bring patients back to work?
    Olofsson T; Petersson IF; Eriksson JK; Englund M; Nilsson JA; Geborek P; Jacobsson LTH; Askling J; Neovius M;
    Ann Rheum Dis; 2017 Jul; 76(7):1245-1252. PubMed ID: 28073801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
    Kristensen LE; Englund M; Neovius M; Askling J; Jacobsson LT; Petersson IF
    Ann Rheum Dis; 2013 Oct; 72(10):1675-9. PubMed ID: 23148309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and drug survival of anti-tumour necrosis factor-alpha therapies in patients with non-radiographic axial spondyloarthritis: an observational cohort study from Southern Sweden.
    Gulfe A; Kapetanovic MC; Kristensen LE
    Scand J Rheumatol; 2014; 43(6):493-7. PubMed ID: 25145283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study.
    Lubrano E; Perrotta FM; Marchesoni A; D'Angelo S; Ramonda R; Addimanda O; Olivieri I; Punzi L; Salvarani C
    J Rheumatol; 2015 Feb; 42(2):258-63. PubMed ID: 25512483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis.
    Baraliakos X; Kiltz U; Peters S; Appel H; Dybowski F; Igelmann M; Kalthoff L; Krause D; Menne HJ; Saracbasi-Zender E; Schmitz-Bortz E; Vigneswaran M; Braun J
    Rheumatology (Oxford); 2017 Jan; 56(1):95-102. PubMed ID: 27997346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for disability pension in a population-based cohort of men and women on long-term sick leave in Sweden.
    Karlsson NE; Carstensen JM; Gjesdal S; Alexanderson KA
    Eur J Public Health; 2008 Jun; 18(3):224-31. PubMed ID: 18245150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
    Malaviya AN; Kalyani A; Rawat R; Gogia SB
    Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice.
    Neovius M; Simard JF; Klareskog L; Askling J;
    Ann Rheum Dis; 2011 Aug; 70(8):1407-14. PubMed ID: 21518724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to recommendations for the use of anti-tumour necrosis factor and its impact over 5 years of follow-up in axial spondyloarthritis.
    López-Medina C; Dougados M; Collantes-Estévez E; Moltó A
    Rheumatology (Oxford); 2018 May; 57(5):880-890. PubMed ID: 29474666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Health Outcomes with Etanercept Treatment in Patients with Early Nonradiographic Axial Spondyloarthritis.
    Dougados M; Tsai WC; Saaibi DL; Bonin R; Bukowski J; Pedersen R; Vlahos B; Kotak S
    J Rheumatol; 2015 Oct; 42(10):1835-41. PubMed ID: 26276968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does disease activity at start of biologic therapy influence work-loss in RA patients?
    Olofsson T; Johansson K; Eriksson JK; van Vollenhoven R; Miller H; Petersson IF; Askling J; Neovius M
    Rheumatology (Oxford); 2016 Apr; 55(4):729-34. PubMed ID: 26683196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consistently Good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial.
    Song IH; Hermann KG; Haibel H; Althoff CE; Poddubnyy D; Listing J; Weiß A; Buß B; Freundlich B; Lange E; Alten R; Rudwaleit M; Sieper J
    J Rheumatol; 2014 Oct; 41(10):2034-40. PubMed ID: 25028375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with tumor necrosis factor inhibitors in axial spondyloarthritis: comparison between private rheumatology practices and academic centers in a large observational cohort.
    Ciurea A; Weber U; Stekhoven D; Scherer A; Tamborrini G; Bernhard J; Toniolo M; Villiger PM; Zufferey P; Kissling RO; Michel BA; Exer P;
    J Rheumatol; 2015 Jan; 42(1):101-5. PubMed ID: 25362654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
    Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
    J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK study.
    Maksymowych WP; Dougados M; van der Heijde D; Sieper J; Braun J; Citera G; Van den Bosch F; Logeart I; Wajdula J; Jones H; Marshall L; Bonin R; Pedersen R; Vlahos B; Kotak S; Bukowski JF
    Ann Rheum Dis; 2016 Jul; 75(7):1328-35. PubMed ID: 26269397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.